Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)

Next Previous
X
Search
Trial Profile

BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms UltIMMa-2
  • Sponsors AbbVie; Boehringer Ingelheim

    • Most Recent Events

    • 21 Mar 2023 Results (n=525 from studies UltIMMa-1, UltIMMa-2 and LIMMitless) assessing the long-term efficacy of RZB in patients with a history of prior biologic use presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results assessing the long-term improvement in difficult-to-treat areas (nail, palmoplantar, scalp) and quality of life after switch from ustekinumab (UST) to risankizumab (RZB) in patients with moderate-to-severe plaque psoriasis from UltlMMA-1 and -2 and the open-label LIMMitless extension study, presented at the American Academy of Dermatology annual Meeting 2023.
    • 21 Mar 2023 Results of pooled analysis (n=1306 from four studies UltIMMa-1 and -2, IMMvent, and IMMhance) assessing racial and ethnic diversity for efficacy and safety outcomes presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top